OR WAIT 15 SECS
Walter Colasante is a vice-president in Charles River Associates’ (CRA’s) Life Sciences Practice.
Pascale Diesel is a vice-president in Charles River Associates’ (CRA’s) Life Sciences Practice.
The highly customized nature of cell and gene therapy production means that manufacturing innovations for one therapy may not be easily transferable to others.
Now that the first cell and gene therapies have become commercial realities and more companies are involved in precision medicine research, different manufacturing platforms are being developed. However, as the authors write, developers need to consider the fundamental differences between these therapies and more traditional biopharmaceuticals to develop the right commercialization strategies.
eBook: Biologics and Sterile Drug Manufacturing 2019
When referring to this article, please cite it as W. Colasante, P. Diesel, and L. Gerlovin, “The Link Between Manufacturing and Commercialization in Gene and Cell Therapies," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2019).